Generation, cryopreservation, function and in vivo persistence of ex vivo expanded cynomolgus monkey regulatory T cells

Cellular Immunology

Volumn 295, Issue 1, 2015, Pages 19-28

  Guo, Hao ^a   Zhang, Hong ^a   Lu, Lien ^a   Ezzelarab, Mohamed B ^a   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cryopreservation; Cynomolgus macaques; Ex vivo expansion; In vivo monitoring; Regulatory T cells

Indexed keywords

CD27 ANTIGEN; CD39 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR T BET; 5-(6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; FORKHEAD TRANSCRIPTION FACTOR; INTERLEUKIN 7 RECEPTOR ALPHA; SUCCINIMIDE DERIVATIVE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; EX VIVO STUDY; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACACA FASCICULARIS; MALE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; ADOPTIVE TRANSFER; ANIMAL; AUTOTRANSPLANTATION; CELL CULTURE; CELL PROLIFERATION; CULTURE TECHNIQUE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MONONUCLEAR CELL; PROCEDURES; TIME; TRANSPLANTATION;

ERAGROSTIS TEF; MACACA; MACACA FASCICULARIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CRYOPRESERVATION; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; SUCCINIMIDES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84923369133     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.02.006     Document Type: Article

References (53)

1. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
2. Joffre O., Santolaria T., Calise D., Al Saati T., Hudrisier D., Romagnoli P., et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat. Med. 2008, 14:88-92.
3. Raimondi G., Sumpter T.L., Matta B.M., Pillai M., Corbitt N., Vodovotz Y., et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J. Immunol. 2010, 184:624-636.
4. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
5. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
6. Roncarolo M.G., Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 2007, 7:585-598.
7. Tang Q., Bluestone J.A., Kang S.M. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J. Mol. Cell. Biol. 2012, 4:11-21.
8. June C.H., Blazar B.R. Clinical application of expanded CD4+25+ cells. Semin. Immunol. 2006, 18:78-88.
9. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 2002, 196:389-399.
10. Golshayan D., Jiang S., Tsang J., Garin M.I., Mottet C., Lechler R.I. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007, 109:827-835.
11. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
12. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004, 104:895-903.
13. Kean L.S., Gangappa S., Pearson T.C., Larsen C.P. Transplant tolerance in non-human primates: progress, current challenges and unmet needs. Am. J. Transplant. 2006, 6:884-893.
14. Torrealba J.R., Katayama M., Fechner J.H., Jankowska-Gan E., Kusaka S., Xu Q., et al. Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. J. Immunol. 2004, 172:5753-5764.
15. Bashuda H., Kimikawa M., Seino K., Kato Y., Ono F., Shimizu A., et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J. Clin. Invest. 2005, 115:1896-1902.
16. Anderson A., Martens C.L., Hendrix R., Stempora L.L., Miller W.P., Hamby K., et al. Expanded nonhuman primate Tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses. Am. J. Transplant. 2008, 8:2252-2264.
17. Dons E.M., Raimondi G., Zhang H., Zahorchak A.F., Bhama J.K., Lu L., et al. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity. Am. J. Transplant. 2013, 13:2169-2178.
18. Singh K., Kozyr N., Stempora L., Kirk A.D., Larsen C.P., Blazar B.R., et al. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am. J. Transplant. 2012, 12:1441-1457.
19. Golab K., Leveson-Gower D., Wang X.J., Grzanka J., Marek-Trzonkowska N., Krzystyniak A., et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int. Immunopharmacol. 2013, 16:371-375.
20. Weinberg A., Song L.Y., Wilkening C., Sevin A., Blais B., Louzao R., et al. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin. Vaccine Immunol. 2009, 16:1176-1186.
21. Costantini A., Mancini S., Giuliodoro S., Butini L., Regnery C.M., Silvestri G., et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J. Immunol. Methods 2003, 278:145-155.
22. Campbell D.J., Koch M.A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 2011, 11:119-130.
23. Lee M.K.T., Moore D.J., Jarrett B.P., Lian M.M., Deng S., Huang X., et al. Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J. Immunol. 2004, 172:6539-6544.
24. Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.
25. Zhang N., Schroppel B., Lal G., Jakubzick C., Mao X., Chen D., et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009, 30:458-469.
26. Beiras-Fernandez A., Thein E., Hammer C. Induction of immunosuppression with polyclonal antithymocyte globulins: an overview. Exp. Clin. Transplant. 2003, 1:79-84.
27. Gaber A.O., Monaco A.P., Russell J.A., Lebranchu Y., Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25years and new frontiers in solid organ transplantation and haematology. Drugs 2010, 70:691-732.
28. Tang Q., Leung J., Melli K., Lay K., Chuu E.L., Liu W., et al. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl. Int. 2012, 25:1257-1267.
29. Coenen J.J., Koenen H.J., van Rijssen E., Hilbrands L.B., Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006, 107:1018-1023.
30. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203:1701-1711.
31. Himmel M.E., MacDonald K.G., Garcia R.V., Steiner T.S., Levings M.K. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J. Immunol. 2013, 190:2001-2008.
32. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
33. Dwyer K.M., Hanidziar D., Putheti P., Hill P.A., Pommey S., McRae J.L., et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant. 2010, 10:2410-2420.
34. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
35. Zheng J., Liu Y., Qin G., Lam K.T., Guan J., Xiang Z., et al. Generation of human Th1-like regulatory CD4+ T cells by an intrinsic IFN-gamma- and T-bet-dependent pathway. Eur. J. Immunol. 2011, 41:128-139.
36. Koch M.A., Tucker-Heard G., Perdue N.R., Killebrew J.R., Urdahl K.B., Campbell D.J. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 2009, 10:595-602.
37. Steiner D., Brunicki N., Blazar B.R., Bachar-Lustig E., Reisner Y. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells. Exp. Hematol. 2006, 34:66-71.
38. Peters J.H., Preijers F.W., Woestenenk R., Hilbrands L.B., Koenen H.J., Joosten I. Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS ONE 2008, 3:e3161.
39. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1467-1477.
40. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:4712-4716.
41. Mottet C., Uhlig H.H., Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 2003, 170:3939-3943.
42. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 2004, 199:1455-1465.
43. Ma A., Qi S., Song L., Hu Y., Dun H., Massicotte E., et al. Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. Int. Immunopharmacol. 2011, 11:618-629.
44. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003, 9:1144-1150.
45. Ermann J., Hoffmann P., Edinger M., Dutt S., Blankenberg F.G., Higgins J.P., et al. Only the CD62L(+) subpopulation of CD4(+)CD25(+) regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
46. Trenado A., Charlotte F., Fisson S., Yagello M., Klatzmann D., Salomon B.L., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 2003, 112:1688-1696.
47. Trzonkowski P., Bieniaszewska M., Juscinska J., Dobyszuk A., Krzystyniak A., Marek N., et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 2009, 133:22-26.
48. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
49. Singh K., Stempora L., Harvey R.D., Kirk A.D., Larsen C.P., Blazar B.R., et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate treg half-life and phenotype after adoptive transfer. Am. J. Transplant. 2014, 14:2691-2703.
50. Hippen K.L., Merkel S.C., Schirm D.K., Sieben C.M., Sumstad D., Kadidlo D.M., et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 2011, 3:83ra41.
51. Peters J.H., Hilbrands L.B., Koenen H.J., Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS One 2008, 3:e2233.
52. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
53. Hippen K.L., Harker-Murray P., Porter S.B., Merkel S.C., Londer A., Taylor D.K., et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008, 112:2847-2857.